The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...

Summit Therapeutics’s drug ivonescimab reduced the risk of lung cancer progression or death by nearly half, compared to MSD’s blockbuster drug Keytruda (pembrolizumab) in Phase III data showcased on 8 ...

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

Merck's Keytruda therapy received approval from the European Union, in combination with antibody-drug Padcev, as a first-line cancer treatment. The pharmaceutical company said Tuesday that the ...

Merck MRK decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

NEW YORK – Merck on Thursday said it is discontinuing the Phase III KEYNOTE-630 trial of Keytruda (pembrolizumab) as adjuvant therapy in patients with high-risk, locally advanced cutaneous squamous ...